CA-VAULTREE
More than 4,100 publicly disclosed data breaches occurred in 2022, with approximately 22 billion records leaked. Most of it was not encrypted. Vaultree, the Data-In-Use Encryption leader, today announced the general availability of a first-of-its-kind software development kit (SDK) to address this massive need.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005361/en/
Vaultree's first-of-its-kind Fully Functional Data-In-Use Encryption toolkit will transform enterprise security. (Graphic: Business Wire)
Made possible by a series of major cryptographic breakthroughs by the Vaultree team, the SDK is a user-friendly, simple-to-integrate, and easy-to-use fully scalable solution that enables organizations to benefit from Fully Functional Data-In-Use Encryption, allowing for the processing of fully encrypted data without server-side decryption and complex intermediaries or noticeable delays in data processing.
Vaultree developed the solution to address the problems associated with processing completely encrypted data at scale, ensuring that companies no longer need to sacrifice security for performance and are able to keep their data safe at all times with unmatched simplicity and exceptional encrypted data processing rates. Businesses can retain their tech stack, database, code and SQL syntax, follow the rules, and operate without any perceptible changes, with the added benefit of being completely encrypted and at scale. Vaultree's SDK provides protection, including adherence, security and effectiveness. So, in the event of a leak, rather than issuing an apology about the wholesale exposure of sensitive data, companies will be able to inform clients that although their data has been compromised, it is encrypted, meaning it is protected by encryption, an unparalleled level of security.
This layer of protection also makes CISOs' lives easier by solving one of the most difficult challenges in cybersecurity: persistent data encryption, even in the event of a leak, with the world's first Fully Functional Data-In-Use Encryption solution. Encryption technologies to date have not been able to process encrypted data, decrypting it to plain text for processing and therefore impacting organizations' overall data security, making their data readily available to cyber criminals. Vaultree's encryption solution is smarter, quicker, easier, and more efficient than anything else on the market. Truly zero-trust, it allows users to work with fully encrypted data without key disclosure or server-side decryption. Data-In-Use Encryption maintains data encrypted at all times, even during processing. As an added benefit, there are no intermediaries, which translates to zero learning curve or implementation overhead, making adoption seamless.
Ease of integration and use is another critical differentiator of Vaultree's SDK encryption solution. There is no need to be a cryptographer, no intermediaries (such as APIs, proxies or plugins), no change of data architecture, and no code or SQL syntax change. This remarkable adaptability has made the product a prime mover in the market.
"Vaultree's groundbreaking solution is the first of its kind and will change the encryption landscape as we know it. Data security is not only one of today's hot topics but also the topic of tomorrow. Vaultree is leading the way to a safer future," said Rinki Sethi, member of Vaultree's executive board of directors.
Vaultree's SDK encryption solution tackles the drawbacks of both conventional and contemporary encryption methods with a variety of features, including:
- Close to plaintext processing speed, even at scale
- Keys reside with the client
- End-to-end encrypted in use, decrypted only client-side
- No changes to stack, SQL syntax, data structure, architecture, and network topology
- Complex processing from fulltext search to computations on randomized encrypted data
- Performance and scalability at enterprise levels
- No need for special purpose hardware
Peak performance processing on fully encrypted data enables enterprises to scale to billions of datasets while processing data at speeds similar to unencrypted data processing. Enterprises handling large amounts of sensitive data, including those in financial services, healthcare, pharmaceutical, insurance, retail, telecom, and energy sectors, will be able to mitigate the tremendous economic, cyber, legal, reputational, and business risk of a data breach in plain text — because of the data being encrypted.
"Breaches or leaks will continue happening, no matter how many tools are in the first line of defense, but the second line of defense — encryption — has been neglected for decades because data still has to be decrypted to be worked with. The only way forward is an always-encrypted approach," said Tilo Weigandt, Co-Founder and COO of Vaultree.
Amongst other developments, Vaultree is the first and only (Data-In-Use) encryption solution vendor to partner with Google's AlloyDB for PostgreSQL, leading a new era with a fully functional encryption solution in the cloud. To further expand usage of its revolutionary data protection solution, Vaultree has also partnered with Qrypt. The partnership leverages Qrypt’s ability to independently generate identical symmetric keys at multiple endpoints and quantum-secure future-safe one-time pad encryption paired with Vaultree’s Fully Functional Data-In-Use Encryption to enable fast, future secure data processing in a cloud-first world.
"As it stands, we are the only company globally with the capacity and innovation we have. We are going to grow significantly over the next year enabling organizations with our Data-In-Use encryption technology. We are focusing heavily on bringing this to market fast with our target markets being North America and Europe," said Ryan Lasmaili, Co-Founder and CEO of Vaultree.
About Vaultree
Vaultree has developed the world's first Fully Functional Data-in-Use Encryption solution that solves the industry's fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare / pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational, and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree's data-in-use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005361/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom